Compare Vertex Pharmaceuticals Incorporated (VRTX) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs GeneDx Holdings Corp — how do they compare? Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 67.8× GeneDx Holdings Corp's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VRTX | WGS | |
|---|---|---|
Market Cap | $121.95B | $1.80B |
Sector | Health | Technology |
52-Week High | $529.59 | $167.51 |
52-Week Low | $366.54 | $34.51 |
Enterprise Value | $116.69B | $1.80B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
